Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (391-400 of 908) with videos related to

Pageof 91
Sort By:
Circulation|September 17, 1998
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) InvestigatorsP M Ridker, N Rifai, M A Pfeffer, et al.
The New England Journal of Medicine|January 7, 2005
C-reactive protein levels and outcomes after statin therapyPaul M Ridker, Christopher P Cannon, David Morrow, et al.
The Journal of Thoracic and Cardiovascular Surgery|March 1, 1987
Clinical comparisons of methods of myocardial protectionP O Daily, T A Pfeffer, J B Wisniewski, et al.
Journal of Diabetes and Its Complications|April 28, 2021
NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trialMagnus O Wijkman, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Cardiac Failure|September 25, 1999
Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injectionS A Grosjean, M A Arstall, R N Mitchell, et al.
Journal of the American College of Cardiology|October 1, 1995
Cost-effectiveness of captopril therapy after myocardial infarctionJ Tsevat, D Duke, L Goldman, et al.
The American Journal of Cardiology|December 1, 1991
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)F M Sacks, M A Pfeffer, L Moye', et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
Circulation|September 17, 2003
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationshipGary F Mitchell, Yves Lacourcière, Jean-Pascal Ouellet, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose, Hicham Skali, Nagesh Anavekar, et al.
Pageof 91

Showing results (391-400 of 908) with videos related to

Sort By:
Pageof 91
Circulation|September 17, 1998
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) InvestigatorsP M Ridker, N Rifai, M A Pfeffer, et al.
The New England Journal of Medicine|January 7, 2005
C-reactive protein levels and outcomes after statin therapyPaul M Ridker, Christopher P Cannon, David Morrow, et al.
The Journal of Thoracic and Cardiovascular Surgery|March 1, 1987
Clinical comparisons of methods of myocardial protectionP O Daily, T A Pfeffer, J B Wisniewski, et al.
Journal of Diabetes and Its Complications|April 28, 2021
NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trialMagnus O Wijkman, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Cardiac Failure|September 25, 1999
Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injectionS A Grosjean, M A Arstall, R N Mitchell, et al.
Journal of the American College of Cardiology|October 1, 1995
Cost-effectiveness of captopril therapy after myocardial infarctionJ Tsevat, D Duke, L Goldman, et al.
The American Journal of Cardiology|December 1, 1991
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)F M Sacks, M A Pfeffer, L Moye', et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
Circulation|September 17, 2003
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationshipGary F Mitchell, Yves Lacourcière, Jean-Pascal Ouellet, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose, Hicham Skali, Nagesh Anavekar, et al.
Pageof 91